Skip to content

Lantern Pharma Inc.: 10-Q filed 2020-10-29

What Lantern Pharma Inc. reported in its quarterly report filed 2020-10-29 (fiscal Q3 2020): 22 published measures, 62 facts as tagged in accession 0001213900-20-033954.

This filing

Form
10-Q (quarterly report)
Filed
2020-10-29
Fiscal period
fiscal Q3 2020
Accession
0001213900-20-033954 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lantern Pharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-09-3022,492,952USD
At 2019-12-311,432,576USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-09-30923,057USD
At 2019-12-31489,292USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-09-3021,569,895USD
At 2020-06-3023,227,869USD
At 2020-03-31536,468USD
At 2019-12-31943,284USD
At 2019-09-301,555,047USD
At 2019-06-301,121,396USD
At 2019-03-311,744,760USD
At 2018-12-31-201,798USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-09-3020,802,542USD
At 2019-12-311,232,030USD
At 2019-09-301,940,906USD
At 2018-12-31445,163USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,701,488USD92
2020-01-01 to 2020-09-30-3,012,186USD274
2019-07-01 to 2019-09-30-669,652USD92
2019-01-01 to 2019-09-30-1,753,018USD273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-4,083,564USD274
2019-01-01 to 2019-09-30-1,419,047USD273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-09-3023,665,221USD274
2019-01-01 to 2019-09-302,920,507USD273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-11,145USD274
2019-01-01 to 2019-09-30-5,717USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-09-30-9,763,891USD
At 2019-12-31-6,751,705USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-09-3017,608USD
At 2019-12-318,758USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2020-07-01 to 2020-09-3043,000USD92
2020-01-01 to 2020-09-30167,000USD274
2019-07-01 to 2019-09-3032,000USD92
2019-01-01 to 2019-09-3054,000USD273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-09-3022,475,344USD
At 2019-12-311,232,818USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-09-30814,557USD
At 2019-12-31489,292USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,701,488USD92
2020-01-01 to 2020-09-303,012,186USD274
2019-07-01 to 2019-09-30669,652USD92
2019-01-01 to 2019-09-301,753,018USD273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-01-01 to 2019-09-3021,000USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-09-306,217,577shares
At 2019-12-311,978,269shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-09-3031,333,164USD
At 2019-12-317,694,547USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2020-09-301,672,802USD
At 2019-12-31788USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2020-07-01 to 2020-09-30-1,701,488USD92
2020-04-01 to 2020-06-30-833,422USD91
2020-01-01 to 2020-03-31-477,276USD91
2019-07-01 to 2019-09-30-669,652USD92
2019-04-01 to 2019-06-30-629,393USD91
2019-01-01 to 2019-03-31-453,973USD90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-07-01 to 2020-09-301,100,719USD92
2020-01-01 to 2020-09-302,117,290USD274
2019-07-01 to 2019-09-30441,251USD92
2019-01-01 to 2019-09-30977,300USD273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2020-01-01 to 2020-09-302,295USD274
2019-01-01 to 2019-09-301,091USD273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-09-30-169,049USD274

Inspect the source

Entity
Lantern Pharma Inc. / CIK 0001763950
Captured
2026-09-21T17:26:28.194Z
SEC response SHA-256
de4123361405efcd0291343ed94db7c24d43e6c36dbcd4d45ba588f463c7f9d1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001763950.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))